Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL193361 | 0.81 | ALDH1A1 (0.48) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL194146 | 0.78 | CYP1A1 (0.47) | MAPTKDM4EALDH1A1MAPK1HTT | |
| SCHEMBL29815731 | 0.78 | CYP1A1 (0.47) | MAPTKDM4EALDH1A1MAPK1HTT | |
| SCHEMBL194572 | 0.77 | GCGR (0.44) | MAPTKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL194014 | 0.77 | MCL1 (0.46) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL6152523 | 0.77 | KDM4E (0.50) | MAPTKDM4EALDH1A1SMN1; SMN2THRB | |
| SCHEMBL195094 | 0.77 | CYP19A1 (0.49) | KDM4EALDH1A1KMT2AGLAMAOA | |
| SCHEMBL14013397 | 0.75 | KDM4E (0.49) | MAPTKDM4EALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL3419967 | 0.74 | MAOA (0.56) | MAPTKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL91929 | 0.74 | MAOA (0.56) | MAPTKDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108129374-A | The method for preparing azole compounds | 武田药品工业株式会社 | 2018-06-08 | — | — | CN | claimed |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-03-23 | — | — | US | disclosed |
| US-11498898-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-11-15 | — | — | US | disclosed |
| CN-114835619-A | Process for preparing azole compounds | 武田药品工业株式会社 | 2022-08-02 | — | — | CN | disclosed |
| EP-3929187-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
| US-10844011-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-11-24 | — | — | US | disclosed |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-04-16 | — | — | US | disclosed |
| EP-3613734-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-11 | — | — | US | disclosed |
| EP-3241826-A2 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-11-08 | — | — | EP | disclosed |
| EP-2765130-B1 | Intermediates for use in a process of producing pyrrole compounds | TAKEDA PHARMACEUTICALS CO (JP) | 2017-07-26 | — | — | EP | disclosed |
| EP-2402313-B1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2016-08-24 | — | — | EP | disclosed |
| US-9266831-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8822694-B2 | Process for producing pyrrole compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2765130-A2 | Process for producing pyrrole compound | Takeda Pharmaceutical Company Limited (JP) | 2014-08-13 | — | — | EP | disclosed |
| EP-2402313-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070705-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-20200115336-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-12351553-B2 | Process for producing 5-aryl-1H-pyrolle-3-carbonitrile compounds by dehalogenation | CYP51A1, PAH, HPD | MAPT 3529/4885KDM4E 807/4885ALDH1A1 1045/4885 |
| US-20230088365-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-11498898-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-20180009746-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-20140303378-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-10844011-B2 | Process for producing pyrrole compound | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
| US-20110306769-A1 | PROCESS FOR PRODUCING PYRROLE COMPOUND | DHPS, STS, HPD | MAPT 4406/4885KDM4E 222/4885ALDH1A1 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.